|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
An overview of the randomised trials. Lancet. 365:1687–1717. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mauri D, Pavlidis N and Ioannidis JP:
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A
meta-analysis. J Natl Cancer Inst. 3:188–194. 2005. View Article : Google Scholar
|
|
4
|
Reese DM and Slamon DJ: HER-2/neu signal
transduction in human breast and ovarian cancer. Stem Cells.
15:1–8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nabholtz JM and Gligorov J:
Docetaxel/trastuzumab combination therapy for the treatment of
breast cancer. Expert Opin Pharmacother. 6:1555–1564. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moasser MM: The oncogene HER2: Its
signaling and transforming functions and its role in human cancer
pathogenesis. Oncogene. 26:6469–6487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oostra DR and Macrae ER: Role of
trastuzumab emtansine in the treatment of HER2-positive breast
cancer. Breast Cancer (Dove Med Press). 6:103–113. 2014.PubMed/NCBI
|
|
11
|
Zhu ZL, Zhang J, Chen ML and Li K:
Efficacy and safety of Trastuzumab added to standard treatments for
HER2-positive metastatic breast cancer patients. Asian Pac J Cancer
Prev. 14:7111–7116. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jelovac D and Wolff AC: The adjuvant
treatment of HER2-positive breast cancer. Curr Treat Options Oncol.
13:230–239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Osoba D, Slamon DJ, Burchmore M and Murphy
M: Effects on quality of life of combined trastuzumab and
chemotherapy in women with metastatic breast cancer. J Clin Oncol.
20:3106–3113. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valachis A, Mauri D, Polyzos NP,
Chlouverakis G, Mavroudis D and Georgoulias V: Trastuzumab combined
to neoadjuvant chemotherapy in patients with HER2-positive breast
cancer: A systematic review and meta-analysis. Breast. 20:485–490.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rastogi P, Anderson SJ, Bear HD, Geyer CE,
Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil
SR, et al: Preoperative chemotherapy: Updates of national surgical
adjuvant breast and Bowel project protocols B-18 and B-27. J Clin
Oncol. 26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin W, Jiang Y, Shen Z, Shao Z and Lu J:
Trastuzumab in the adjuvant treatment of HER2-positive early breast
cancer patients: A meta-analysis of published randomized controlled
trials. PLoS One. 6:e210302011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Azim HA Jr, de Azambuja E, Paesmans M and
Piccart-Gebhart MJ: Sequential or concurrent administration of
trastuzumab in early breast cancer? Too early to judge. J Clin
Oncol. 28:e353–e354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Perez EA, Suman VJ, Davidson NE, Sledge
GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle
JN, et al: Cardiac safety analysis of doxorubicin and
cyclophosphamide followed by paclitaxel with or without trastuzumab
in the north central cancer treatment group N9831 adjuvant breast
cancer trial. J Clin Oncol. 26:1231–1238. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bria E, Cuppone F, Fornier M, Nisticò C,
Carlini P, Milella M, Sperduti I, Terzoli E, Cognetti F and
Giannarelli D: Cardiotoxicity and incidence of brain metastases
after adjuvant trastuzumab for early breast cancer: The dark side
of the moon? A meta-analysis of the randomized trials. Breast
Cancer Res Treat. 109:231–239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan-Chiu E, Yothers G, Romond E, Geyer CE
Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L,
et al: Assessment of cardiac dysfunction in a randomized trial
comparing doxorubicin and cyclophosphamide followed by paclitaxel,
with or without trastuzumab as adjuvant therapy in node-positive,
human epidermal growth factor receptor 2-overexpressing breast
cancer: NSABP B-31. J Clin Oncol. 23:7811–7819. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. BMJ. 339:b25352009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holmes DR: Intraoperative radiotherapy in
breast conserving surgery. J Surg Oncol. 110:68–74. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Higgins JP, Altman DG, Gøtzsche PC, Jüni
P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L and Sterne JA:
Cochrane Bias Methods Group; Cochrane Statistical Methods Group:
The Cochrane collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343:d59282011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bucher HC, Guyatt GH, Griffith LE and
Walter SD: The results of direct and indirect treatment comparisons
in meta-analysis of randomized controlled trials. J Clin Epidemiol.
50:683–691. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Loke YK, Pradhan S, Yeong JK and Kwok CS:
Comparative coronary risks of apixaban, rivaroxaban and dabigatran:
A meta-analysis and adjusted indirect comparison. Br J Clin
Pharmacol. 78:707–717. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang N and Sobieraj DM: Indirect treatment
comparison of new oral anticoagulants for the treatment of acute
venous thromboembolism. Thromb Res. 133:1145–1151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Slamon D, Eiermann W, Robert N, Pienkowski
T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et
al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J
Med. 365:1273–1283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perez EA, Romond EH, Suman VJ, Jeong JH,
Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA and
Wolmark N: Four-year follow-up of trastuzumab plus adjuvant
chemotherapy for operable human epidermal growth factor receptor
2-positive breast cancer: Joint analysis of data from NCCTG N9831
and NSABP B-31. J Clin Oncol. 29:3366–3373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gianni L, Dafni U, Gelber RD, Azambuja E,
Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch
C, et al: Treatment with trastuzumab for 1 year after adjuvant
chemotherapy in patients with HER2-positive early breast cancer: A
4-year follow-up of a randomised controlled trial. Lancet Oncol.
12:236–244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
von Minckwitz G, du Bois A, Schmidt M,
Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann
M, Bauer W, et al: Trastuzumab beyond progression in human
epidermal growth factor receptor 2-positive advanced breast cancer:
A german breast group 26/breast international group 03–05 study. J
Clin Oncol. 27:1999–2006. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Spielmann M, Roché H, Delozier T, Canon
JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels
JP, et al: Trastuzumab for patients with axillary-node-positive
breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol.
27:6129–6134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Joensuu H, Bono P, Kataja V, Alanko T,
Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S,
Möykkynen K, et al: Fluorouracil, epirubicin and cyclophosphamide
with either docetaxel or vinorelbine, with or without trastuzumab,
as adjuvant treatments of breast cancer: Final results of the
FinHer Trial. J Clin Oncol. 27:5685–5692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gasparini G, Gion M, Mariani L, Papaldo P,
Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F,
Spada A, et al: Randomized Phase II Trial of weekly paclitaxel
alone versus trastuzumab plus weekly paclitaxel as first-line
therapy of patients with Her-2 positive advanced breast cancer.
Breast Cancer Res Treat. 101:355–365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Marty M, Cognetti F, Maraninchi D, Snyder
R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A,
et al: Randomized phase II trial of the efficacy and safety of
trastuzumab combined with docetaxel in patients with human
epidermal growth factor receptor 2-positive metastatic breast
cancer administered as first-line treatment: The M77001 study
group. J Clin Oncol. 23:4265–4274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Steger GG, Greil R, Lang A, Rudas M,
Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E,
Hubalek M, et al: Epirubicin and docetaxel with or without
capecitabine as neoadjuvant treatment for early breast cancer:
Final results of a randomized phase III study (ABCSG-24). Ann
Oncol. 25:366–371. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pierga JY, Delaloge S, Espié M, Brain E,
Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM,
Spielmann M, Savignoni A and Marty M: A multicenter randomized
phase II study of sequential epirubicin/cyclophosphamide followed
by docetaxel with or without celecoxib or trastuzumab according to
HER2 status, as primary chemotherapy for localized invasive breast
cancer patients. Breast Cancer Res Treat. 122:429–437. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gianni L, Eiermann W, Semiglazov V,
Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M,
Lichinitser M, et al: Neoadjuvant chemotherapy with trastuzumab
followed by adjuvant trastuzumab versus neoadjuvant chemotherapy
alone, in patients with HER2-positive locally advanced breast
cancer (the NOAH trial): A randomised controlled superiority trial
with a parallel HER2-negative cohort. Lancet. 375:377–384. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Buzdar AU, Valero V, Ibrahim NK, Francis
D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE,
Hunt KK, et al: Neoadjuvant therapy with paclitaxel followed by
5-fluorouracil, epirubicin and cyclophosphamide chemotherapy and
concurrent trastuzumab in human epidermal growth factor receptor
2-positive operable breast cancer: An update of the initial
randomized study population and data of additional patients treated
with the same regimen. Clin Cancer Res. 13:228–233. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Buzdar AU, Ibrahim NK, Francis D, Booser
DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano
SH, et al: Significantly higher pathologic complete remission rate
after neoadjuvant therapy with trastuzumab, paclitaxel and
epirubicin chemotherapy: Results of a randomized trial in human
epidermal growth factor receptor 2-positive operable breast cancer.
J Clin Oncol. 23:3676–3685. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
World Health Organisation: WHO handbook
for reporting results of cancer treatment. WHO offset publication
no 48. World Health Organisation. (Geneva, Switzerland). 1979.
|
|
46
|
Khokher S, Qureshi MU and Chaudhry NA:
Comparison of WHO and RECIST criteria for evaluation of clinical
response to chemotherapy in patients with advanced breast cancer.
Asian Pac J Cancer Prev. 13:3213–3218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Olson EM, Abdel-Rasoul M, Maly J, Wu CS,
Lin NU and Shapiro CL: Incidence and risk of central nervous system
metastases as site of first recurrence in patients with
HER2-positive breast cancer treated with adjuvant trastuzumab. Ann
Oncol. 24:1526–1533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Brollo J, Curigliano G, Disalvatore D,
Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L,
Locatelli M, Manunta S and Goldhirsch A: Adjuvant trastuzumab in
elderly with HER-2 positive breast cancer: A systematic review of
randomized controlled trials. Cancer Treat Rev. 39:44–50. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Petrelli F and Barni S: Meta-analysis of
concomitant compared to sequential adjuvant trastuzumab in breast
cancer: The sooner the better. Med Oncol. 29:503–510. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liao C, Yin F, Huang P, Cao Y and Gao F: A
meta-analysis of randomized controlled trials comparing
chemotherapy plus trastuzumab with chemotherapy alone in
HER-2-positive advanced breast cancer. Breast J. 17:109–111. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dahabreh IJ, Linardou H, Siannis F,
Fountzilas G and Murray S: Trastuzumab in the adjuvant treatment of
early-stage breast cancer: A systematic review and meta-analysis of
randomized controlled trials. Oncologist. 13:620–630. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Moja L, Tagliabue L, Balduzzi S, Parmelli
E, Pistotti V, Guarneri V and D'Amico R: Trastuzumab containing
regimens for early breast cancer. Cochrane Database Syst Rev.
4:CD0062432012.PubMed/NCBI
|
|
53
|
Piccart-Gebhart MJ, Procter M,
Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga
J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med.
353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Russell SD, Blackwell KL, Lawrence J,
Pippen JE Jr, Roe MT, Wood F, Paton V, Holmgren E and Mahaffey KW:
Independent adjudication of symptomatic heart failure with the use
of doxorubicin and cyclophosphamide followed by trastuzumab
adjuvant therapy: A combined review of cardiac data from the
national surgical adjuvant breast and Bowel project B-31 and the
north central cancer treatment group N9831 clinical trials. J Clin
Oncol. 28:3416–3421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Procter M, Suter TM, de Azambuja E, Dafni
U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT,
Toi M, et al: Longer-term assessment of trastuzumab-related cardiac
adverse events in the Herceptin adjuvant (HERA) trial. J Clin
Oncol. 28:3422–3428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
de Azambuja E, Bedard PL, Suter T and
Piccart-Gebhart M: Cardiac toxicity with anti-HER-2 therapies: What
have we learned so far? Target Oncol. 4:77–88. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
